Nasdaq: RAPP
Rapport Therapeutics insiders
The officers, directors and 10% owners of Rapport Therapeutics, Inc. who hold the most stock, valued at the live RAPP price.
$23.59
RAPP today +$190K (+0.81%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 6
- Their RAPP stock
- $341M
- Market value
- $1.40B
- Held by ranked insiders
- 24.4%
Insiders by value of RAPP holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | Third Rock Ventures V, L.P. | Director | 6,518,620 | $154M | 11.0% | Corporate |
| 2 | Third Rock Ventures VI, L.P. | 10% owner | 6,432,715 | $152M | 10.9% | Corporate |
| 3 | Steven M. Paul | Director | 555,022 | $13.1M | 0.94% | 3876th |
| 4 | Abraham Ceesay | Chief Executive Officer | 552,493 | $13.0M | 0.93% | 6746th |
| 5 | David Bredt | Chief Scientific Officer | 393,075 | $9.3M | 0.66% | 9296th |
| 6 | John Maraganore | Director | 9,411 | $222K | <0.1% | 1983rd |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for Rapport Therapeutics; see each profile for the filing.